Epidermal growth factor (EGF) and insulin-like growth factor I (IGF-I) are potent mitogens in human breast cancer and both act via membrane-associated receptors with intrinsic tyrosine kinase activity. The influence of IGF-I in regulating breast cancer cell proliferation appears to be under steroid hormone control at a number of levels. Oestrogen has been reported to up-regulate IGF-I receptor (IGFR) expression, possibly sensitising tumour cells to the mitogenic effect of IGF-I (Stewart et al., 1990 ) and a positive relationship between oestrogen receptor (ER) and IGFR expression has been reported (Pekonen et al., 1988) . Conversely, progestins appear to down-regulate IGFR numbers (Papa et al., 1991; Owens et al., 1993) . Tamoxifen has been reported to reduce circulating levels of IGF-I (Pollack et al., 1992) , and the pattern of expression of IGF binding proteins (IGFBPs), which can both attenuate and potentiate the actions of IGF-I, is influenced by both oestrogens and antioestrogens (Lonning, 1992; Owens et al., 1993; Lahti et al., 1994; Manni et al., 1994) . It is generally accepted that tumour expression of receptors for epidermal growth factor (EGFR) is a powerful prognostic indicator in human breast cancer, with high EGFR numbers being associated with low ER content and poor clinical prognosis (Harris, 1989) . Recent evidence has suggested that the EGF and IGF receptor systems may influence one another at several levels. Administration of EGF or oestradiol to ovariectomised mice increases uterine IGF-I mRNA production (Hana and Murphy, 1994) suggesting that activation of the IGF receptor system may be a common down-stream event for both oestradiol-and EGF-induced cell proliferation. It has been reported that EGF can regulate IGFBP expression (Andreatta van Leyen et al., 1994; Hembree et al., 1994) . The relationship between EGFR and IGFR expression is less clear. Since a positive ER status is associated with a positivity for IGFR (Pekonen et al., 1988) and low EGFR levels (Harris, 1989) , an inverse relationship between EGFR and IGFR expression might be anticipated. However such a relationship has not been clearly demonstrated to date (Pekonen et al., 1988) .
We have previously shown that acquired tamoxifen resistance accompanied by loss of detectable ERs and progesterone receptors (PGRs) in the ZR-75-1 human breast cancer cell line (Van den Berg et al., 1989) is associated with an increase in EGFR expression (Long et al., 1992) , in agreement with clinical findings (Harris, 1989) . Conversely, an oestrogen-independent variant of the same cell line, which constitutively expresses high numbers of PGRs (Van den Berg et al., 1990) , has a much reduced EGFR content (Long et al., 1992) . In this study we (Keightly and Cressie, 1980 (Table I) . Figure 2 compares IGFR expression in the three cell lines with previously published data for EGFR expression (Long et al., 1992) . It can be seen that there is a clear inverse relationship between IGFR and EGFR expression in the variant cell lines ZR-PR-LT and ZR-75-9al while ZR-75-1 cells express similar numbers of both receptors. (Nicholson, 1988; Harris, 1989) . In contrast, the oestrogenindependent ZR-PR-LT line has much reduced EGFR numbers accompanying elevated PGR expression (Van den Berg, 1990) . In this study we have shown that these changes in EGFR expression associated with tamoxifen resistance and oestrogen independence respectively are paralleled by opposite changes in IGFR expression (Table I) . While the parent cell line expresses similar numbers of EGFR and IGFR, in the variant lines, EGFR and IGFR expression is inversely related (Figure 2 ). These data suggest that EGFR and IGFR expression in ZR-75-1 cells are linked, with changes in the level of expression of one receptor being reflected by an opposite change in the expression of the other. There is evidence to support the concept of receptor crosstalk for EGFR and IGFR. Administration of EGF to ovariectomised mice increases uterine IGF-I mRNA production (Hana and Murphy, 1994) and it has been reported that EGF can regulate IGFBP-3 expression, thus sensitising cells to the effects of IGF-I. (Andreatta van Leyen et al., 1994; Hembree et al., 1994) . It is possible that EGF sensitising of cells to IGF may occur more effectively in the face of high EGFR/low IGFR levels, while sensitisation would be less effective when EGFR numbers are low, and perhaps unnecessary when corresponding IGFR numbers are high.
Since there is good evidence that ER and EGFR expression is inversely related in breast cancer, (Nicholson, 1988; Harris, 1989) and there is a positive relationship between ER and IGFR expression (Pekonen et al., 1988; Railo et al., 1994) , it might be expected that an inverse relationship between IGFR and EGFR expression would exist. Clinical studies have failed to establish such a relationship (Pekonen et al., 1988; Foekens et al., 1989) . The reasons for this are unknown, but may be due to inappropriate cut-off points for receptor positivity, occupation of receptors by endogeneous ligands and other factors. To our knowledge, our data are the first to show an inverse relationship between IGFR and EGFR expression in human breast cancer cell lines in vitro. Whereas EGFR expression is elevated only 3-fold in the ZR-75-9al tamoxifen-resistant line 480 compared with the parent line (Figure 2) , the EGFR/IGFR ratios in the two cell lines are 0.75 and 12.5 respectively. Should such a relationship exist in vivo it is possible that an EGFR/IGFR ratio may provide a more sensitive prognostic indicator for antioestrogen resistance than EGFR expression alone.
We have shown that oestradiol increases IGF binding by the oestrogen-sensitive ZR-75-1 cell line, (Figure 3 ), in agreement with earlier studies (Stewart et al., 1990) . As expected, oestradiol was without effect in the ZR-75-9al line, which lacks oestrogen receptors (Van den Berg et al., 1989) . Although the mechanism is unknown, the observation that low concentrations of oestradiol reduces ['25I]IGF-I binding by ZR-PR-LT cells would be consistent with our earlier findings that oestradiol inhibits ZR-PR-LT cell proliferation (Van den Berg et al., 1990) . Elevated expression of IGFR by the oestrogen-independent ZR-PR-LT line is consistent with the observation that another oestradiol-induced protein (PGR) is also overexpressed in this cell line in the absence of oestrogenic stimulation (Van den Berg et al., 1990) . (Papa et al., 1991) . However, a different cell line (T47D) and different progestins (progesterone and R5020) were used in the latter study and the down regulation of IGFR reported was attributed to a progestin-induced increase in IGF-II secretion. The failure of the present study to demonstrate IGFR down regulation may in part be explained by the report that ZR-75-1 cells do not secrete IGF-II (Osborne et al., 1989) . Taken together with these earlier studies, our findings emphasise the complexity of potential interactions between steroid and peptide growth factor receptors. To our knowledge, this report is the first to indicate that IGFR expression may also be increased by glucocorticoids, and that high concentrations of a progestin may increase ['251]IGF-I binding via the glucocorticoid receptor. The physiological significance of these findings is unclear, as progestins and glucocorticoids are generally growth inhibitory towards breast cancer cells in vitro and down regulation of a receptor for a potent mitogen such as IGF-I would be more consistent with these anti-proliferative effects. In this context it is of interest that progestins and glucocorticoids have also been shown to increase EGFR expression in a number of human breast cancer cell lines (Ewing et al., 1989) .
In conclusion, we have demonstrated an inverse relationship between EGFR and IGFR receptor expression by human breast cancer cells in vitro. Regardless of basal IGFR expression by the cell lines studied, [1251] IGF-I binding is increased following exposure to a progestin and this effect may be mediated via both PGRs and glucocorticoid receptors.
